cloud

Tirzepatide vs Semaglutide: A Comparative Study on Efficacy and Side Effects in Type 2 Diabetes

author
By: BNN Correspondents
Tirzepatide vs Semaglutide: A Comparative Study on Efficacy and Side Effects in Type 2 Diabetes

Tirzepatide Shows More Promising Results

A recent meta-analysis of randomized trials revealed that Tirzepatide, a medication for type 2 diabetes, has been associated with higher reductions in HbA1c and weight when compared to Semaglutide. Despite the promising results, both drugs were found to increase the risk of adverse gastrointestinal events, emphasizing the importance of a well-rounded consideration of the efficacy and potential side effects.

Study Highlights

The research, led by a team from Aristotle University of Thessaloniki in Greece, suggests that Tirzepatide could emerge as a preferred option for specific patients, especially those where weight management is a priority. However, it is crucial to consider the complete safety profile of the drug, patient preferences, and cost-effectiveness in different healthcare settings before making any decisions.

Methodology and Results

The study analyzed randomized controlled trials assessing a maintenance dose of 5 mg, 10 mg, or 15 mg once-weekly Tirzepatide or 0.5 mg, 1 mg, or 2 mg once-weekly subcutaneous Semaglutide compared with placebo for at least 12 weeks. The trials were sourced from the MEDLINE and Cochrane Library databases.

The results showed that Tirzepatide 15 mg offered the highest HbA1c reduction with a 2% decrease compared to placebo. Furthermore, all three Tirzepatide doses outperformed Semaglutide in terms of body weight loss. Tirzepatide 15 mg led to a weight loss of 10.96 kg more than placebo, while high-dose Semaglutide 2 mg resulted in a weight loss of 5.24 kg more than placebo.

Adverse Gastrointestinal Events

On the flip side, Tirzepatide 15 mg was linked to the highest risks for nausea, vomiting, and diarrhea compared to placebo. Adults receiving Tirzepatide 15 mg had a greater risk for vomiting than those receiving Semaglutide 1 mg and a higher risk for vomiting and nausea than adults receiving Semaglutide 0.5 mg.

Need for Further Studies

Despite the promising results, the study’s lead researcher notes the need for more studies to assess cardiovascular and renal outcomes with Semaglutide. A long-term cardiovascular trial comparing Tirzepatide with Dulaglutide, another glucose-lowering medication, is currently underway. Additionally, there is a need for valid country-specific cost-effectiveness evaluations comparing Tirzepatide with Semaglutide and other glucose-lowering medications.

0
logo

Join the revolution today with our BNN App.

appstore googleplay
Learn more arrow
Analysis Greece Health

Comments

There are no comments yet.
Log in to comment
Latest Headlines
World News
AP Bren Triumphs: Advances to M5 World Championship Knockout Stages
AP Bren Triumphs: Advances to M5 World Championship Knockout Stages
Dame Esther Rantzen Passes the Childline Baton to Daughter Amid Health Concerns
Dame Esther Rantzen Passes the Childline Baton to Daughter Amid Health Concerns
Debate Night Showdown: Hinderaker Analyzes Republican Candidates' Performances
Debate Night Showdown: Hinderaker Analyzes Republican Candidates' Performances
Ursula von der Leyen: Forbes' Most Powerful Woman of the World
Ursula von der Leyen: Forbes' Most Powerful Woman of the World
Mallu Bhatti Vikramarka Sworn in as Telangana's Deputy Chief Minister
Mallu Bhatti Vikramarka Sworn in as Telangana's Deputy Chief Minister
Presidential Elections Announced in Russia and Azerbaijan for Early 2024
Presidential Elections Announced in Russia and Azerbaijan for Early 2024
Cuba’s New Regulation Impacts Citizens Travelling Abroad
Cuba’s New Regulation Impacts Citizens Travelling Abroad
Israel Calls for International Support to Weaken Hamas' Hold on Gaza Amidst Ongoing Conflict
Israel Calls for International Support to Weaken Hamas' Hold on Gaza Amidst Ongoing Conflict
Winter Wellness: Vital Vitamins for Combating Seasonal Affective Disorder
Winter Wellness: Vital Vitamins for Combating Seasonal Affective Disorder
Rising Concern Over 'White Lung Syndrome' Linked to Pneumonia
Rising Concern Over 'White Lung Syndrome' Linked to Pneumonia
'Kneecap': Irish Language Cinema Breaks New Ground at Sundance
'Kneecap': Irish Language Cinema Breaks New Ground at Sundance
IUMS Calls for Global Action in Support of Gaza and Protection of Al Aqsa Mosque
IUMS Calls for Global Action in Support of Gaza and Protection of Al Aqsa Mosque
Global Healthcare Developments: Digital Enhancements, Strikes, and New Initiatives
Global Healthcare Developments: Digital Enhancements, Strikes, and New Initiatives
2023 Nobel Laureates Convene Ahead of Official Award Ceremony
2023 Nobel Laureates Convene Ahead of Official Award Ceremony
Rise in Covid-19 Detection in Wastewater Signals Possible Resurgence
Rise in Covid-19 Detection in Wastewater Signals Possible Resurgence
Paris Attack Targets Vel d'Hiv Children's Memorial Garden: A Wake-up Call to France's Persistent Terrorism Threat
Paris Attack Targets Vel d'Hiv Children's Memorial Garden: A Wake-up Call to France's Persistent Terrorism Threat
Global News: From Turkish Education Shifts to Google's New Copyright Agreement
Global News: From Turkish Education Shifts to Google's New Copyright Agreement
'Oppenheimer' Set for Release in Japan Amid Controversy and Anticipation
'Oppenheimer' Set for Release in Japan Amid Controversy and Anticipation
bnn wechat
BNN

BNN Breaking

Magazines & Newspapers

Free - In Google Play

Install Open in app